ZYBERNO
Stock Report
Updated Sep 1, 2026

BIOMERICA, INC. (BMRA)

Healthcare • NASDAQ

$2.07

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
20.0/100
POOR BUSINESS
BIOMERICA, INC. (BMRA) scores 20/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-98.1%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.12x)
Operating Margin (Operational Efficiency):CRITICAL (-123.8%)
Return on Capital (Capital Efficiency):CRITICAL (-138.3%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

BIOMERICA, INC. (BMRA) stock report — Zyberno Score 20/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:2.07
Market Cap:$6.23M

Valuation Multiples (3)

P/B Ratio:1.88x
P/S Ratio:1.44x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$5.82M

Price Action & Momentum (3)

Momentum Percentile:10 / 100
% of 52-Week High:64.3%
B. Profitability Assessment

Return Metrics (5)

ROA:-70.4%
Reinvestment Rate:2.2%
Fundamental Growth Rate (g):-3.0%

Margin Analysis (3)

Operating Margin Ttm:-123.8%
Net Margin Ttm:-96.5%
Ebitda Margin:-122.5%

TTM Performance (3)

Gross Margin Ttm:11.7%
Operating Margin Ttm:-123.8%
Net Margin Ttm:-96.5%

Yield Metrics (2)

Earnings Yield:-$180.38
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-145.3%
Latest Earnings Filed:2026-04-13

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-17.7%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.64x
Quick Ratio:1.59x
Cash Ratio:0.86x

Leverage Analysis (3)

Debt To Equity Ttm:0.12x
Debt-to-Equity Ratio:0.12x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:2,562,000.00
Cash And Cash Equivalents:1,336,000.00
Long Term Debt:$193.00K
Net Debt:-$413.00K
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $4.33M
Linear Growth: -17.7%
📊 Click to view full BMRA Revenue analysis & methodology →
Cost Of Revenue Ttm:$4.14M

Profitability Breakdown (2)

Gross profit TTM: $505.00K
Linear Growth: -33.8%
📊 Click to view full BMRA Gross Profit analysis & methodology →
-$5.36M

Bottom Line Performance (3)

-$4.17M
Income Before Tax:-$4.15M
Ebitda Ttm:-5,301,000.00

Operating Expenses (5)

Operating Expenses:5,539,000.00
R And D Expense:835,000.00
Sga Expense:4,704,000.00
Income Tax Expense:$20.00K
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:84.6%
Sga To Revenue Percentage:476.6%
Ebitda Margin:-122.5%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$4.88M
Current Assets:$4.12M
Ppe Net:91,000.00
Goodwill:0.00
Intangible Assets:$231.00K

Liability Structure (4)

Total Liabilities:1,561,000.00
Current Liabilities:1,561,000.00
Long Term Debt:$193.00K
Short Term Debt:$730.00K

Equity & Capital (3)

Equity:$3.32M
Retained Earnings:-$55.80M
Common Stock:25,000,000.00

Working Capital Items (3)

Accounts Receivable:941,000.00
Inventory:1,645,000.00
Accounts Payable:730,000.00

Special Items (2)

Contract Liabilities:30,000.00
Stock Based Compensation:58,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$2.77M$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$920.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:939,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:54,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-2.85
-$2.85
Earnings Per Share Ttm:-$1.39

Revenue & Cash Per Share (2)

Sales Per Share Ttm:1.44
Operating Cash Flow Per Share:-$1.28

Book Value & Capital (2)

Book Value Per Share:$1.10
Cash Per Share:0.44

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.73x
Working Capital Turnover Ttm:1.69x

Receivables Management (2)

Receivables Turnover Ttm:4.60x
Days Sales Outstanding Ttm:79.40

Inventory Management (2)

Inventory Turnover Ttm:2.52x
Days Inventory Outstanding Ttm:144.96

Payables & Cash Cycle (2)

Days Payable Outstanding:64.33
Cash Conversion Cycle:160.03
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:2.2%
Fundamental Growth Rate (g):-3.0%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-17.7%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):-33.8%
Book Value Growth Rate (Linear):-18.9%
C. Company Profile & Context

Corporate Information (6)

Symbol:BMRA
Company Name:BIOMERICA, INC.
Sector:Healthcare
Industry:Medical Diagnostics
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:3.01M
Shares Outstanding Basic:3.01M
Shares Outstanding Diluted:3.01M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 17:48:12 UTC
Data Timestamp:2026-08-22T01:07:56.510280
Scroll to Top